Articles by Jen Jiang

Jennifer is a University of Western Ontario graduate with a degree in International Business. She strives to excel as a content creator in the digital sphere, working with clients in the Finance and Tech industry to leverage clickable taglines, images, and articles in driving traffic. When not writing, Jennifer enjoys photography, copywriting, and video production.

Bravatek Solutions, Inc. Enters New Addendum With DarkPulse Tech

Oct 24 Jen Jiang

A few days ago, Bravatek Solutions, Inc. (OTC:$BVTK) entered into an Addendum to the Strategic Alliance Agreement with DarkPulse Technology Holdings, Inc, a New York corporation involved in the manufacturing hardware and software based on ... [Read]

Price Target Update on Spectrum Pharmaceuticals, Inc.

Oct 24 Jen Jiang

Spectrum Pharmaceuticals, Inc. (NASDAQ:$SPPI) plundered a cool -2.43% with the closing price of $18.90 as of morning trading. The overall volume in the last trading session was 2.7 million shares. ROI is a form of ... [Read]

Before Investing in Community Health Systems Inc: Understand Beta

Oct 24 Jen Jiang

If you are interested in investing in Community Health Systems Inc. (NYSE:$CYH) or currently own the stock, then you must understand its beta in order to successfully minimize risks to your portfolio. Specifically, there are ... [Read]

Why You Should Keep an Eye on Trans Global Group, Inc.

Oct 24 Jen Jiang

Trans Global Group, Inc. (OTC:$TGGI) is gaining attention from investors after it proposed a new growth strategy, including marijuana licenses in a process from multiple states. Specifically, TGG trumpets itself as a company, through its ... [Read]

SunPower Corporation Registers a 2.84% Price Change After Morning Session

Oct 24 Jen Jiang

As of morning trading, SunPower Corporation (NASDAQ:$SPWR) stock saw a move of 2.84% with the closing price of $6.87. During the past week, the company saw a total shift of 1.93%. Over the last three ... [Read]

3D Signatures Announces Successful Clinical Trial Completion in New Lymphoma Drug

Oct 24 Jen Jiang

3D Signatures, Inc. (TSXV:DXD) officially announced that the company had completed the clinical trial component, or Stage 3, of its Hodgkin’s lymphoma test validation program. Data from the clinical trial has been further submitted to ... [Read]

Imperva, Inc. Expected to Report Upwards of $83.07 Million in Sales This Quarter

Oct 24 Jen Jiang

According to the Zacks Investment Research report, Equities analysts forecast that Imperva, Inc. (NYSE:$IMPV) will see sales of $83.07 million for the current quarter. Seven analysts have issued estimates for Imperva’s earnings. The lowest sales ... [Read]

Articles by Jen Jiang

Bravatek Solutions, Inc. Enters New Addendum With DarkPulse Tech

Price Target Update on Spectrum Pharmaceuticals, Inc.

Before Investing in Community Health Systems Inc: Understand Beta

Why You Should Keep an Eye on Trans Global Group, Inc.

SunPower Corporation Registers a 2.84% Price Change After Morning Session

3D Signatures Announces Successful Clinical Trial Completion in New Lymphoma Drug

Imperva, Inc. Expected to Report Upwards of $83.07 Million in Sales This Quarter

Anavex Life Sciences Corp.: Top Holders Statistics

Patriot One Technologies, Inc. Announces Increase to Previous Bought Deal Financing

A Look At Dolcat Ventures Inc.’s Recent Performance